sa¹ú¼Ê´«Ã½¹ÙÍøÍøÒ³Èë¿Ú

Abstract: Liquid nasal drug delivery has evolved from simple local therapies into a highly versatile platform supporting rapid systemic delivery, emergency rescue medications, and emerging CNS‑targeted treatments.

Abstract: Modern drug development is being tested on two fronts: molecules are increasingly difficult to formulate, and global manufacturing routes are increasingly difficult to rely on.

Abstract: Spray drying has evolved beyond amorphous solid dispersions to become a scalable, versatile manufacturing platform for small molecules, peptides, biologics, and emerging modalities.

Abstract:​ Pharmaceutical micronization, the process of reducing active pharmaceutical ingredient (API) particles to micrometer scale through advanced particle engineering technology, is essential for improving drug bioavailability and performance across diverse therapeutic applications.

Poorly soluble oral small molecules often face compounded development risks, including food effects, high dose requirements, variability in exposure, and the need for rapid onset.

Abstract: Pulmonary drug delivery is no longer limited to asthma and COPD. The field now spans hundreds of active programs, many led by emerging biotechs that must make early, high-impact decisions with limited data.

Abstract: Selling CDMO services is a complex task that calls for broad skill and technical depth.

Summary:​ Drug development today is shaped by 2 forces: the technical challenge of formulating complex molecules and the external challenge of navigating unstable global supply chains.

Catalent’s micronization services help innovators overcome the toughest drug development challenges.

A clinical-stage biotech focused on neurology faced challenges with a lipophilic, oxidation-sensitive molecule limited by solubility, stability, and scalability.